Tenaya Therapeutics Inc. has received FDA clearance of its IND application to begin clinical testing of TN-301, a highly selective small-molecule inhibitor of histone deacetylase 6 (HDAC6) initially being developed for heart failure with preserved ejection fraction (HFpEF).
Investigators described preclinical data for AZD-5462 (Astrazeneca plc/Mitsubishi Tanabe Pharma Corp.), a novel oral agonist of the relaxin family peptide receptor 1 (RXFP1), being developed for the treatment of cardiorenal disease.
Doxorubicin is widely used as an anticancer agent, but it is associated with cardiotoxicity. Follistatin like 3 (FSTL3) is known to be involved in the regulation of cardiac hypertrophy and heart failure.
Researchers presented data from a study that aimed to evaluate pentraxin-3 (PTX3) as a circulating marker of inflammation in patients with suspected myocarditis.
Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged nucleotides reported to be useful for the treatment of cardiovascular and cerebrovascular disorders.
I-Cordis LLC has been awarded a phase II Small Business Innovation Research (SBIR) grant for US$1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for heart failure with preserved ejection fraction (HFpEF).
Atrial fibrillation (AF) is a very common diagnosed arrhythmia and catheter ablation is an effective treatment, but recurrence occurs after catheter ablation and remains a medical challenge. MicroRNAs can be easily detected in the circulation, and they are epigenetic regulators in many biological processes; their usefulness as biomarkers of risk stratification in patients with AF was investigated.
Researchers from University Hospital Bonn presented data from a study that aimed to evaluate the significance of serum levels of the endoplasmic-reticulum-stress chaperone GRP78 in patients undergoing coronary angiography for suspected coronary artery disease (CAD).
RSS
